Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2696686 | 0.98 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2ATML3MBTL1GAA | |
| Pyrrolidine SCHEMBL4931392 | 0.88 | CA2 (0.42) | ALDH1A1SMN1; SMN2ATML3MBTL1GAA | |
| SCHEMBL4880196 | 0.82 | KMT2A (0.48) | L3MBTL1TDP1KMT2AHTT | |
| SCHEMBL4212544 | 0.82 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2ATMGAATDP1 | |
| SCHEMBL4219173 | 0.80 | FAAH (0.39) | ALDH1A1SMN1; SMN2ATMTDP1MEN1 | |
| SCHEMBL2696781 | 0.80 | L3MBTL1 (0.53) | ALDH1A1SMN1; SMN2L3MBTL1GAAMEN1 | |
| SCHEMBL4216418 | 0.80 | TDP1 (0.46) | SMN1; SMN2L3MBTL1TDP1KMT2AHTT | |
| SCHEMBL4870186 | 0.79 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL10063641 | 0.76 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2ATML3MBTL1GAA | |
| SCHEMBL14477743 | 0.74 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2ATML3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874433-A | Pyrimidine compound and synthetic method and application thereof | 上海应用技术大学 | 2023-10-13 | — | — | CN | claimed |
| CN-116874433-A | Pyrimidine compound and synthetic method and application thereof | 上海应用技术大学 | 2023-10-13 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9828349-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | EXONHIT THERAPEUTICS SA (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9828349-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | EXONHIT THERAPEUTICS SA (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-9399628-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399628-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9314466-B2 | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9314466-B2 | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-1841423-A2 | USE OF 1- BENZYL-1- HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3 HYDROXY-2-AMINO PROPIONIC ACID AMIDES AND RELATED COMPOUNDS AS ANALGESICS | Allergan, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1841742-A1 | 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | Allergan, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1841743-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | Allergan, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081252-A2 | USE OF 1-BENZYL-1-HYDR0XY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS AS ANALGESICS | ALLERGAN, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006081273-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROAYRYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY | ALLERGAN, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006081276-A1 | 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-7041831-B2 | Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050075381-A1 | Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | HIRTH BRADFORD H (US) | 2005-04-07 | — | — | US | disclosed |
| US-6835831-B2 | Efficient synthesis of ceramide-like compounds by reacting an aldehyde and an amidomethylisonitrile to form a 4-amido-2-oxazoline; suppress biosynthesis of glycosphingolipids; antitumor agents; Tays-Sach, Gaucher's | GENZYME CORPORATION | 2004-12-28 | — | — | US | disclosed |
| US-20030153768-A1 | Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075381-A1 | Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGGT1, UGCG, OGT | ALDH1A1 183/4885SMN1; SMN2 3407/4885ATM 3429/4885 |
| US-20030153768-A1 | Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGGT1, OGT, UGCG | ALDH1A1 177/4885SMN1; SMN2 3458/4885ATM 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.